Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT

Hirabayashi, Shigeki; Uozumi, Ryuji; Kondo, Tadakazu; Arai, Yasuyuki; Kawata, Takahito; Uchida, Naoyuki; Marumo, Atsushi; Ikegame, Kazuhiro; Fukuda, Takahiro; Eto, Tetsuya; Tanaka, Masatsugu; Wake, Atsushi; Kanda, Junya; Kimura, Takafumi; Tabuchi, Ken; Ichinohe, Tatsuo; Atsuta, Yoshiko; Yanada, Masamitsu; Yano, Shingo

doi:10.1002/cam4.3920

Cited by 2 publications

(1 citation statement)

References 52 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a period of remission, relapse episodes are frequent with more drug-resistant leukemic clones leading patients to death due to disease complications, and only 24% of patients achieve a 5year overall survival (Hirabayashi et al, 2021). Unfortunately, combination of re-induction protocols with target therapies (for example, tyrosine kinase inhibitors) did not produce any longer survival in the patients (Daver et al, 2020).…”

Section: Acute Myeloid Leukemia: General Aspects and Clinical Featuresmentioning

confidence: 99%

The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia

Pimenta

Varela

Datoguia

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Bone marrow (BM) is a highly complex tissue that provides important regulatory signals to orchestrate hematopoiesis. Resident and transient cells occupy and interact with some well characterized niches to produce molecular and cellular mechanisms that interfere with differentiation, migration, survival, and proliferation in this microenvironment. The acute myeloid leukemia (AML), the most common and severe hematological neoplasm in adults, arises and develop in the BM. The osteoblastic, vascular, and reticular niches provide surface co-receptors, soluble factors, cytokines, and chemokines that mediate important functions on hematopoietic cells and leukemic blasts. There are some evidences of how AML modify the architecture and function of these three BM niches, but it has been still unclear how essential those modifications are to maintain AML development. Basic studies and clinical trials have been suggesting that disturbing specific cells and molecules into the BM niches might be able to impair leukemia competencies. Either through niche-specific molecule inhibition alone or in combination with more traditional drugs, the bone marrow microenvironment is currently considered the potential target for new strategies to treat AML patients. This review describes the cellular and molecular constitution of the BM niches under healthy and AML conditions, presenting this anatomical compartment by a new perspective: as a prospective target for current and next generation therapies.

show abstract

Section: Acute Myeloid Leukemia: General Aspects and Clinical Featuresmentioning

confidence: 99%